Medicine and Dentistry
Ovarian Cancer
100%
Uterine Cancer
90%
Gynecological Oncology
68%
Neoplasm
67%
Krukenberg Tumor
50%
Overall Survival
45%
Diseases
39%
Malignant Neoplasm
37%
Recurrent Disease
33%
Oncology
31%
Cervical Cancer
30%
Paclitaxel
24%
Fallopian Tube
20%
Progression Free Survival
20%
Metastatic Carcinoma
20%
Cancer
19%
Female Genital Tract Cancer
16%
Radiation Therapy
15%
Hydrocortisone
14%
Body Mass Index
14%
Quality of Life
13%
Bevacizumab
13%
Hazard Ratio
13%
Adjuvant Therapy
12%
Oncologist
12%
Wound Complication
11%
Cancer Cell
11%
Pelvis
11%
Carcinosarcoma
11%
Multivariate Analysis
11%
Tumor Progression
10%
Cell Line
10%
Chemoradiotherapy
10%
Tumor Cell
10%
Endometrium Carcinoma
10%
Intensity Modulated Radiation Therapy
10%
Biological Marker
9%
Kaplan Meier Method
9%
Tumor Microenvironment
9%
Proportional Hazards Model
9%
Clinical Trial
9%
Positron Emission Tomography
9%
Recurrent Ovarian Cancer
9%
Doxorubicin
9%
Interleukin 6
8%
Primary Peritoneal Cancer
8%
Immunohistochemistry
8%
Cisplatin
8%
Carboplatin
8%
Homologous Recombination
8%
Keyphrases
Ovarian Cancer
74%
Endometrial Cancer
63%
Overall Survival
43%
Gynecologic Oncology
37%
Chemotherapy
32%
Gynecologic Oncology Group
31%
Ovarian Cancer Patients
30%
NRG Oncology
29%
Tumor
29%
Group Studies
27%
Paclitaxel
25%
Oncology Patients
25%
Epithelial Ovarian Cancer
25%
Fallopian Tube
22%
Confidence Interval
21%
Cervical Cancer
18%
Cancer Patients
18%
Ovarian Carcinoma
18%
Primary Peritoneal Cancer
17%
Bevacizumab
17%
Quality of Life
16%
Gynecological Cancer
16%
Progression-free Survival
15%
Advanced Ovarian Cancer
14%
Adjuvant Therapy
14%
Endometrioid Endometrial Cancer
13%
Tumor Growth
12%
Gynecologic Oncologist
12%
Tumor Microenvironment
12%
Wound Complications
11%
Hazard Ratio
11%
Body Mass Index
11%
Tumor Cells
11%
Ovarian Cancer Cells
11%
Recurrent Endometrial Cancer
10%
Cortisol
10%
Cervical Cancer Patients
10%
Interleukin-6
10%
Risk Factors
10%
Cisplatin
10%
Multivariate Analysis
10%
Vascular Endothelial Growth Factor
9%
Intensity-modulated Radiation Therapy
9%
Obesity
9%
High-grade Serous Ovarian Cancer (HGSOC)
9%
High Risk
9%
Phase II Trial
9%
AEE788
9%
Uterine Serous Carcinoma
9%
Metastasis
9%